SCHEMBL5545150

SCHEMBL5545150

CCCCCCOC(=O)[N]CC

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.55
EPHX1 P07099 1/20 0.52
TSHR P16473 3/20 0.50
FAAH O00519 2/20 0.50
HCAR2 Q8TDS4 1/20 0.47
RAD52 P43351 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
ACHE P22303 6/20 0.46
DGKA P23743 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546849 0.98 NAAA (0.52) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL970929 0.91 ALDH1A1 (0.54) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7692541 0.86 NAAA (0.53) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7693494 0.86 NAAA (0.53) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7689067 0.86 NAAA (0.53) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7693662 0.86 NAAA (0.53) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7692519 0.86 NAAA (0.53) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7687504 0.83 NAAA (0.50) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL7691818 0.83 NAAA (0.50) NAAAEPHX1TSHRFAAHHCAR2
SCHEMBL1566316 0.83 NAAA (0.50) NAAAEPHX1TSHRFAAHHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed
EP-0355661-A2 Direct positive image forming method FUJI PHOTO FILM CO., LTD. (JP) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NAAA 2414/4885EPHX1 4071/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.